Pneumococcal conjugate vaccine breakthrough infections: 2001–2016
TA Adebanjo, T Pondo, D Yankey, HA Hill… - …, 2020 - publications.aap.org
BACKGROUND: Most countries use 3-dose pneumococcal conjugate vaccine (PCV)
schedules; a 4-dose (3 primary and 1 booster) schedule is licensed for US infants. We …
schedules; a 4-dose (3 primary and 1 booster) schedule is licensed for US infants. We …
Uptake of 13-valent pneumococcal conjugate vaccine among US adults aged 19 to 64 years with immunocompromising conditions
J Vietri, J Harnett, B Emir, E Chilson - Human Vaccines & …, 2020 - Taylor & Francis
ABSTRACT The CDC Advisory Committee on Immunization Practices (ACIP) recommended
immunization with the recently licensed 13-valent pneumococcal conjugate vaccine …
immunization with the recently licensed 13-valent pneumococcal conjugate vaccine …
Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United …
R Kandasamy, M Voysey, S Collins… - The Journal of …, 2020 - academic.oup.com
Background Following programmatic introduction of the 13-valent pneumococcal conjugate
vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes …
vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes …
Pneumococcal vaccination in people living with HIV
J Thornhill, A Sivaramakrishnan, C Orkin - Vaccine, 2015 - Elsevier
Streptococcus pneumoniae is the leading bacterial opportunistic infection (OI) in HIV
positive individuals. Anti-retroviral treatment (ART) reduces their risk of Invasive …
positive individuals. Anti-retroviral treatment (ART) reduces their risk of Invasive …
Challenges in Inferring Pneumococcal Conjugate Vaccine Impact From Bacterial Surveillance Data
Pneumococcal cases occurring after PCV introduction could be unvaccinated because they
were too young or too old to receive PCV when it was introduced. Analyses that are …
were too young or too old to receive PCV when it was introduced. Analyses that are …
[HTML][HTML] Epidemiology of serotype 1 invasive pneumococcal disease, South Africa, 2003–2013
C von Mollendorf, C Cohen, S Tempia… - Emerging Infectious …, 2016 - ncbi.nlm.nih.gov
Abstract In South Africa, 7-valent pneumococcal conjugate vaccine (PCV) was introduced in
April 2009 and replaced with 13-valent PCV in April 2011. We describe the epidemiology of …
April 2009 and replaced with 13-valent PCV in April 2011. We describe the epidemiology of …
[HTML][HTML] Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the …
Background Invasive pneumococcal disease (IPD) is a major cause of pediatric morbidity
and mortality. Pneumococcal conjugate vaccines (PCVs) were introduced in the US in 2000 …
and mortality. Pneumococcal conjugate vaccines (PCVs) were introduced in the US in 2000 …
Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD
S Ben-Shimol, D Greenberg, N Givon-Lavi… - Vaccine, 2016 - Elsevier
Background The worldwide introduction of pneumococcal conjugate vaccines (PCV) into
National Immunization Programs resulted in rapid and substantial reduction of invasive …
National Immunization Programs resulted in rapid and substantial reduction of invasive …
Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children< 5 years: an active prospective nationwide …
S Ben-Shimol, D Greenberg, N Givon-Lavi… - Vaccine, 2014 - Elsevier
Background The 7-valent pneumococcal conjugated vaccine (PCV7) was introduced to the
Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 …
Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 …
Effects of vaccination on invasive pneumococcal disease in South Africa
A Von Gottberg, L De Gouveia, S Tempia… - … England Journal of …, 2014 - Mass Medical Soc
Background In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …